Modular Medical Inc

Modular Medical Inc(MODD)股票分析

$1.330

+0.052 (+3.91%)收盘时

Loading chart…
最高
1.455
开盘
1.360
成交量加权均价
1.35
成交量
54.69K
市值
50.76M
最低
1.255
成交额
73.65K
企业价值/息税折旧摊销前利润(TTM)
0.00

Modular Medical, Inc. is a medical device company. The Company is focused on the design, development, and commercialization of insulin pumps using technology to increase pump adoption in the diabetes marketplace. The Company's product seeks to serve both the type 1 and type 2 diabetes markets for those individuals requiring insulin. MODD1, its product, is a high-precision pump. MODD1's features include three parts - one reusable, two disposable - snap together to form the working system; one button interface; 90-day reusable, three-day disposable; removable system, slim profile, lighter weight, and no external controller required, no charging and no battery replacement. Its pump product comprises the pump, a disposable cartridge that holds the insulin reservoir, a baseplate that affixes the pump product to the user's body and the infusion set, which includes a cannula to infuse the insulin into the body.

AI 分析 of Modular Medical Inc (MODD)

卖出

Modular Medical Inc (MODD) is not a good buy right now due to its significant financial losses and poor technical indicators. The current price is $1.33, with an RSI of 24.997 indicating it is oversold. The company has reported a staggering year-to-date change of -88.48% and a 1-year change of -91.30%, reflecting severe declines in stock value. Furthermore, the forward P/E ratio is 0, suggesting no earnings growth is expected in the near future. The main risk is the continued negative net income, which reached -7,790,000 USD in Q2 2026. Given these factors, it is advisable to sell rather than buy at this time.

估值指标

Modular Medical Inc(MODD)当前预期市盈率为 0.00,5 年平均预期市盈率为 -2.57。

预期市盈率

严重高估
5 年均值 P/E
-2.57
当前P/E
0.00
高估
-1.37
低估
-3.77

预期 EV/EBITDA

严重低估
5 年均值 EV/EBITDA
0.00
当前EV/EBITDA
0.00
高估
0.00
低估
0.00

预期市销率

合理
5 年均值 P/S
136.48
当前P/S
3.80
高估
395.58
低估
-122.61

事件时间线

2026-10-15 (ET)

09:30:00

Modular Medical Launches Digital Education Resources for Diabetes Patients

2026-09-04 (ET)

08:30:00

Modular Medical Secures Contract with U.S. National Pharmacy Benefit Manager

2026-09-03 (ET)

08:30:00

Modular Medical Receives FDA Approval for Software Enhancements

2026-08-03 (ET)

08:30:00

Modular Medical Plans to Launch Tubeless Patch Pump in Five U.S. Markets in October 2026

2026-07-23 (ET)

08:30:00

Modular Medical Forms Pivot Innovation Council

资讯

MODD 常见问题 —— 由 Alphio AI 解答

Modular Medical, Inc. is a medical device company. The Company is focused on the design, development, and commercialization of insulin pumps using technology to increase pump adoption in the diabetes marketplace. The Company's product seeks to serve both the type 1 and type 2 diabetes markets for those individuals requiring insulin. MODD1, its product, is a high-precision pump. MODD1's features include three parts - one reusable, two disposable - snap together to form the working system; one button interface; 90-day reusable, three-day disposable; removable system, slim profile, lighter weight, and no external controller required, no charging and no battery replacement. Its pump product comprises the pump, a disposable cartridge that holds the insulin reservoir, a baseplate that affixes the pump product to the user's body and the infusion set, which includes a cannula to infuse the insulin into the body. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Modular Medical Inc (MODD) is not a good buy right now due to its significant financial losses and poor technical indicators. The current price is $1.33, with an RSI of 24.997 indicating it is oversold. The company has reported a staggering year-to-date change of -88.48% and a 1-year change of -91.30%, reflecting severe declines in stock value. Furthermore, the forward P/E ratio is 0, suggesting no earnings growth is expected in the near future. The main risk is the continued negative net income, which reached -7,790,000 USD in Q2 2026. Given these factors, it is advisable to sell rather than buy at this time.

暂无帖子

注册或登录后参与讨论

相关文章

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易